ADS Therapeutics

ADS Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation targeted cancer therapies. Based in Birmingham, Alabama, the company was founded as a spin-off from the University of Alabama at Birmingham (UAB) to commercialize its proprietary Active Delivery System (ADS) platform. This technology enables the precise delivery of potent therapeutic agents, specifically ribosome-inactivating proteins (RIPs) like saporin, directly into the cytoplasm of cancer cells. By improving the efficiency of intracellular delivery, ADS Therapeutics aims to create treatments that are more effective than traditional antibody-drug conjugates while maintaining a superior safety profile. The company is currently advancing its platform through early-stage research targeting various solid tumors and hematological malignancies.